Biotech Values

[dewophile]

Shire also gave up the other biosimilar it inherited after the acquisition. Given the focus of the company is totally different and the fact these assets require significant marketing expenses (unless you get interchangeable) I think it's far more likely rights reverted to mnta bc of a lack of fit vs specific concerns e the drug itself. Jmo I bought mnta today